Unified Medical Language System® (UMLS®)
2012AB MedDRA Source Information
Counts
| Attribute Name | Description | Count (MRSAT.RRF) |
|---|---|---|
| SMQ_TERM_ADDVERSION | Standardised MedDRA Query (SMQ) Addition Version. Version of MedDRA in which term was added to the SMQ. | 118064 |
| SMQ_TERM_CAT | Standardised MedDRA Query (SMQ) Term Category. A single alphabetical letter indicating the category of the term for application of the SMQ algorithm. If the SMQ does not use algorithms, then all Term_category values are assigned "A." For a child SMQ, this field is assigned "S." | 118064 |
| SMQ_TERM_LMVERSION | Standardised MedDRA Query (SMQ) Last Modified Version. Version of MedDRA in which term was last modified in the SMQ. | 118064 |
| SMQ_TERM_SCOPE | Standardised MedDRA Query (SMQ) Term Scope. Defines the MedDRA term as a member of the broad scope (1), narrow scope (2) of the SMQ search, or a child SMQ (0) (zero). | 118064 |
| SMQ_TERM_STATUS | Standardised MedDRA Query (SMQ) Term Status. Identifies a term as active ("A") or inactive ("I") within this SMQ. | 118064 |
| SMQ_TERM_WEIGHT | Standardised MedDRA Query (SMQ) Term Weight. Used for some SMQ algorithms; "0" is used as default. | 118064 |
| SMQ_TERM_LEVEL | Standardised MedDRA Query (SMQ) Term Level. The MedDRA hierarchy level of a term (4=PT, 5=LLT) or 0 (zero) for a child SMQ. | 39019 |
| MPS | MedDRA primary SOC (PTs may have multiple treepositions, but each has a primary soc) | 19550 |
| SMQ_ALGO | Standardised MedDRA Query (SMQ) Algorithm. Boolean expression of algorithm for the SMQ. "N" if the SMQ does not utilize an algorithm. | 203 |
| SMQ_LEVEL | Standardised MedDRA Query (SMQ) Level. Value between 1 and 5 identifying the level of the SMQ within the hierarchy of SMQs; 1 is the most general, 5 is the most narrow. | 203 |
| SMQ_STATUS | Standardised MedDRA Query (SMQ) Status. "A" = active; "I" = inactive. | 203 |
| SMQ_SOURCE | Standardised MedDRA Query (SMQ) Source. Source for the development of the SMQ, e.g. medical references. | 163 |
| SOS | Scope Statement | 106 |
| MISO | MedDRA Serial Code International SOC Sort Order Digit (01-26) | 26 |
Notes
- Attributes included every discrete piece of information about a concept, an atom, or a relationship that is not part of the basic Metathesaurus concept structure or distributed in one of the relationship files.
- Attribute Names (ATN) are based on source documentation or NLMs understanding of the source.
- Sample attribute values (ATV) are provided for each ATN in the source.
- Sample data highlight examples of ATNs and Attribute Values (ATV) in MRSAT.RRF.
- See Metathesaurus Documentation for a complete list of attribute names.
- See Section 2.5 of the UMLS Reference Manual for more information on attributes in the UMLS Metathesaurus.
Sample Data
SMQ_TERM_ADDVERSION
(return to top)| CUI | METAUI | STYPE | ATN | ATV | STR |
|---|---|---|---|---|---|
| C1869008 | R92105430 | RUI | SMQ_TERM_ADDVERSION | 8.0 | Acute renal failure (SMQ) |
| C1444565 | R92095369 | RUI | SMQ_TERM_ADDVERSION | 10.0 | Cardiopulmonary failure |
| C1869023 | R92107183 | RUI | SMQ_TERM_ADDVERSION | 10.0 | Haemolytic disorders (SMQ) |
| C0011609 | R92069189 | RUI | SMQ_TERM_ADDVERSION | 8.0 | Drug eruption NOS |
| C0235342 | R92080742 | RUI | SMQ_TERM_ADDVERSION | 8.1 | Necrosis mouth |
| C0038218 | R92102949 | RUI | SMQ_TERM_ADDVERSION | 8.1 | Asthmatic crisis |
| C0018378 | R92072990 | RUI | SMQ_TERM_ADDVERSION | 8.1 | Guillain Barre syndrome |
| C0027868 | R92081107 | RUI | SMQ_TERM_ADDVERSION | 8.1 | Neuromyopathy |
| C0156006 | R92065648 | RUI | SMQ_TERM_ADDVERSION | 9.0 | Chronic or unspecified duodenal ulcer with hemorrhage, with obstruction |
| C0549453 | R92073061 | RUI | SMQ_TERM_ADDVERSION | 9.0 | Haematoma traumatic |
| C0263836 | R92073527 | RUI | SMQ_TERM_ADDVERSION | 9.0 | Hemarthrosis involving upper arm |
| C1869102 | R92112282 | RUI | SMQ_TERM_ADDVERSION | 9.0 | Haemorrhage terms (excl laboratory terms) (SMQ) |
| C0151693 | R92098118 | RUI | SMQ_TERM_ADDVERSION | 9.0 | Haemorrhage adrenal |
| C0220887 | R92098227 | RUI | SMQ_TERM_ADDVERSION | 9.0 | Other immediate postpartum haemorrhage, postpartum |
| C0683357 | R92070587 | RUI | SMQ_TERM_ADDVERSION | 9.0 | Excessive drinking |
| C0151576 | R92067605 | RUI | SMQ_TERM_ADDVERSION | 9.0 | CPK increased |
| C1869046 | R92114318 | RUI | SMQ_TERM_ADDVERSION | 9.0 | Neuroleptic malignant syndrome (SMQ) |
| C0004245 | R92062220 | RUI | SMQ_TERM_ADDVERSION | 9.1 | Atrioventricular block NOS |
| C0038525 | R92073766 | RUI | SMQ_TERM_ADDVERSION | 9.1 | Hemorrhage subarachnoid |
SMQ_TERM_CAT
(return to top)| CUI | METAUI | STYPE | ATN | ATV | STR |
|---|---|---|---|---|---|
| C0877723 | R92081283 | RUI | SMQ_TERM_CAT | A | Nonallopathic lesions of cervical region, not elsewhere classified |
| C1963962 | R92104487 | RUI | SMQ_TERM_CAT | A | Direct bilirubin abnormal |
| C0151798 | R92077313 | RUI | SMQ_TERM_CAT | A | Liver necrosis |
| C1869020 | R92106823 | RUI | SMQ_TERM_CAT | A | Liver infections (SMQ) |
| C1141915 | R92099501 | RUI | SMQ_TERM_CAT | A | Hepatitis E antibody abnormal |
| C0857104 | R92071494 | RUI | SMQ_TERM_CAT | A | Florid follicular conjunctivitis |
| C0236071 | R92067229 | RUI | SMQ_TERM_CAT | B | Constriction throat |
| C0235551 | R92069685 | RUI | SMQ_TERM_CAT | B | Edema laryngotracheal |
| C1869038 | R92107752 | RUI | SMQ_TERM_CAT | C | Anaphylactic reaction (SMQ) |
| C1869026 | R92108672 | RUI | SMQ_TERM_CAT | A | Agranulocytosis (SMQ) |
| C0522035 | R92069661 | RUI | SMQ_TERM_CAT | A | Edema arms |
| C1869027 | R92109027 | RUI | SMQ_TERM_CAT | A | Angioedema (SMQ) |
| C0575081 | R92059836 | RUI | SMQ_TERM_CAT | A | Abnormality of gait |
| C0031117 | R92081119 | RUI | SMQ_TERM_CAT | A | Neuropathy peripheral |
| C0014591 | R92073716 | RUI | SMQ_TERM_CAT | A | Hemorrhage nasal |
| C0340775 | R92093103 | RUI | SMQ_TERM_CAT | A | Vein, ruptured varicose |
| C1869046 | R92114533 | RUI | SMQ_TERM_CAT | D | Neuroleptic malignant syndrome (SMQ) |
| C0155658 | R92060403 | RUI | SMQ_TERM_CAT | A | Acute myocardial infarction, subendocardial infarction, subsequent episode of care |
| C1869050 | R92115439 | RUI | SMQ_TERM_CAT | C | Anticholinergic syndrome (SMQ) |
SMQ_TERM_LMVERSION
(return to top)| CUI | METAUI | STYPE | ATN | ATV | STR |
|---|---|---|---|---|---|
| C1869023 | R92107145 | RUI | SMQ_TERM_LMVERSION | 8.0 | Haemolytic disorders (SMQ) |
| C1869024 | R92107365 | RUI | SMQ_TERM_LMVERSION | 8.0 | Severe cutaneous adverse reactions (SMQ) |
| C1112611 | R92099127 | RUI | SMQ_TERM_LMVERSION | 8.1 | Oropharyngitis |
| C1869027 | R92109079 | RUI | SMQ_TERM_LMVERSION | 8.1 | Angioedema (SMQ) |
| C0877638 | R92093962 | RUI | SMQ_TERM_LMVERSION | 8.1 | Wheezing aggravated |
| C1869029 | R92109662 | RUI | SMQ_TERM_LMVERSION | 8.1 | Dyslipidaemia (SMQ) |
| C0002886 | R92061269 | RUI | SMQ_TERM_LMVERSION | 8.1 | Anaemia macrocytic |
| C1869037 | R92110536 | RUI | SMQ_TERM_LMVERSION | 8.1 | Peripheral neuropathy (SMQ) |
| C1869102 | R92111226 | RUI | SMQ_TERM_LMVERSION | 12.0 | Haemorrhage terms (excl laboratory terms) (SMQ) |
| C1869102 | R92112496 | RUI | SMQ_TERM_LMVERSION | 12.0 | Haemorrhage terms (excl laboratory terms) (SMQ) |
| C1869043 | R92113649 | RUI | SMQ_TERM_LMVERSION | 9.0 | Hyperglycaemia/new onset diabetes mellitus (SMQ) |
| C0241442 | R92086515 | RUI | SMQ_TERM_LMVERSION | 11.1 | Protrusion tongue |
| C1869047 | R92114693 | RUI | SMQ_TERM_LMVERSION | 9.0 | Systemic lupus erythematosus (SMQ) |
| C0856480 | R92066774 | RUI | SMQ_TERM_LMVERSION | 9.1 | Confusional state (organic, acute or subacute) |
| C1869050 | R92115641 | RUI | SMQ_TERM_LMVERSION | 9.1 | Anticholinergic syndrome (SMQ) |
| C1869062 | R92117486 | RUI | SMQ_TERM_LMVERSION | 9.1 | Retroperitoneal fibrosis (SMQ) |
| C1869062 | R92117489 | RUI | SMQ_TERM_LMVERSION | 9.1 | Retroperitoneal fibrosis (SMQ) |
| C1869070 | R92118732 | RUI | SMQ_TERM_LMVERSION | 10.0 | Dementia (SMQ) |
| C2363826 | R103656373 | RUI | SMQ_TERM_LMVERSION | 11.1 | SI QIII TIII pattern |
SMQ_TERM_SCOPE
(return to top)| CUI | METAUI | STYPE | ATN | ATV | STR |
|---|---|---|---|---|---|
| C1869007 | R92105055 | RUI | SMQ_TERM_SCOPE | 1 | Rhabdomyolysis/myopathy (SMQ) |
| C0877560 | R92097009 | RUI | SMQ_TERM_SCOPE | 1 | Edema due to renal disease |
| C1869024 | R92107445 | RUI | SMQ_TERM_SCOPE | 2 | Severe cutaneous adverse reactions (SMQ) |
| C1112608 | R92099121 | RUI | SMQ_TERM_SCOPE | 2 | Hypocytosis |
| C0522035 | R92069754 | RUI | SMQ_TERM_SCOPE | 1 | Edema upper limb |
| C0002994 | R92098294 | RUI | SMQ_TERM_SCOPE | 2 | Oedema angioneurotic |
| C1869027 | R92109339 | RUI | SMQ_TERM_SCOPE | 1 | Angioedema (SMQ) |
| C1536916 | R92065409 | RUI | SMQ_TERM_SCOPE | 2 | Cholesterol depletion |
| C1869029 | R92109745 | RUI | SMQ_TERM_SCOPE | 2 | Dyslipidaemia (SMQ) |
| C0018378 | R92072992 | RUI | SMQ_TERM_SCOPE | 2 | Guillain-Barre syndrome |
| C1869039 | R92110873 | RUI | SMQ_TERM_SCOPE | 2 | Depression and suicide/self-injury (SMQ) |
| C1869040 | R92111196 | RUI | SMQ_TERM_SCOPE | 2 | Suicide/self-injury (SMQ) |
| C0391922 | R92070094 | RUI | SMQ_TERM_SCOPE | 2 | Enteritis hemorrhagic |
| C0155789 | R92081831 | RUI | SMQ_TERM_SCOPE | 2 | Oesophageal varices with bleeding |
| C1504419 | R92102463 | RUI | SMQ_TERM_SCOPE | 2 | Pelvic hemorrhage |
| C0553732 | R92086496 | RUI | SMQ_TERM_SCOPE | 1 | Prothrombin level decreased |
| C1869043 | R92113412 | RUI | SMQ_TERM_SCOPE | 1 | Hyperglycaemia/new onset diabetes mellitus (SMQ) |
| C1869044 | R92113742 | RUI | SMQ_TERM_SCOPE | 2 | Interstitial lung disease (SMQ) |
| C1735908 | R92104237 | RUI | SMQ_TERM_SCOPE | 2 | Myocardial ischemia recurrent |
SMQ_TERM_STATUS
(return to top)| CUI | METAUI | STYPE | ATN | ATV | STR |
|---|---|---|---|---|---|
| C1869007 | R92105135 | RUI | SMQ_TERM_STATUS | A | Rhabdomyolysis/myopathy (SMQ) |
| C0019004 | R92073079 | RUI | SMQ_TERM_STATUS | A | Haemodialysed |
| C0034063 | R92069697 | RUI | SMQ_TERM_STATUS | A | Edema lung |
| C0235996 | R92087047 | RUI | SMQ_TERM_STATUS | A | Raised liver enzymes |
| C1869017 | R92106575 | RUI | SMQ_TERM_STATUS | A | Hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions (SMQ) |
| C1869027 | R92108798 | RUI | SMQ_TERM_STATUS | A | Angioedema (SMQ) |
| C1869027 | R92109244 | RUI | SMQ_TERM_STATUS | A | Angioedema (SMQ) |
| C1869028 | R92109497 | RUI | SMQ_TERM_STATUS | A | Asthma/bronchospasm (SMQ) |
| C0857322 | R92061285 | RUI | SMQ_TERM_STATUS | A | Anaemic |
| C1168156 | R92100183 | RUI | SMQ_TERM_STATUS | A | Segmented neutrophil percentage decreased |
| C1869102 | R92111515 | RUI | SMQ_TERM_STATUS | A | Haemorrhage terms (excl laboratory terms) (SMQ) |
| C1869102 | R92111603 | RUI | SMQ_TERM_STATUS | A | Haemorrhage terms (excl laboratory terms) (SMQ) |
| C1869102 | R92111785 | RUI | SMQ_TERM_STATUS | A | Haemorrhage terms (excl laboratory terms) (SMQ) |
| C0024050 | R92095685 | RUI | SMQ_TERM_STATUS | A | Lower gastrointestinal hemorrhage |
| C0149745 | R92080077 | RUI | SMQ_TERM_STATUS | A | Mouth ulcer |
| C1869048 | R92115203 | RUI | SMQ_TERM_STATUS | A | Taste and smell disorders (SMQ) |
| C1869050 | R92115821 | RUI | SMQ_TERM_STATUS | A | Anticholinergic syndrome (SMQ) |
| C2609416 | R92116239 | RUI | SMQ_TERM_STATUS | A | Arrhythmia related investigations, signs and symptoms (SMQ) |
| C0085621 | R92084173 | RUI | SMQ_TERM_STATUS | I | Paralysis spastic |
SMQ_TERM_WEIGHT
(return to top)| CUI | METAUI | STYPE | ATN | ATV | STR |
|---|---|---|---|---|---|
| C1869006 | R92104871 | RUI | SMQ_TERM_WEIGHT | 0 | Torsade de pointes/QT prolongation (SMQ) |
| C0235851 | R92100749 | RUI | SMQ_TERM_WEIGHT | 0 | Hyperbilirubinemia aggravated |
| C1869017 | R92106474 | RUI | SMQ_TERM_WEIGHT | 0 | Hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions (SMQ) |
| C1869017 | R92106623 | RUI | SMQ_TERM_WEIGHT | 0 | Hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions (SMQ) |
| C1869020 | R92106871 | RUI | SMQ_TERM_WEIGHT | 0 | Liver infections (SMQ) |
| C1869023 | R92107057 | RUI | SMQ_TERM_WEIGHT | 0 | Haemolytic disorders (SMQ) |
| C1112208 | R92098766 | RUI | SMQ_TERM_WEIGHT | 0 | Septic phlebitis |
| C0600260 | R92077641 | RUI | SMQ_TERM_WEIGHT | 0 | Lung disease obstructive |
| C1141929 | R92099535 | RUI | SMQ_TERM_WEIGHT | 0 | Gastrointestinal oedema |
| C1869028 | R92109484 | RUI | SMQ_TERM_WEIGHT | 0 | Asthma/bronchospasm (SMQ) |
| C1869029 | R92109532 | RUI | SMQ_TERM_WEIGHT | 0 | Dyslipidaemia (SMQ) |
| C1869037 | R92110344 | RUI | SMQ_TERM_WEIGHT | 0 | Peripheral neuropathy (SMQ) |
| C1869102 | R92112190 | RUI | SMQ_TERM_WEIGHT | 0 | Haemorrhage terms (excl laboratory terms) (SMQ) |
| C1869102 | R92112211 | RUI | SMQ_TERM_WEIGHT | 0 | Haemorrhage terms (excl laboratory terms) (SMQ) |
| C1869047 | R92115131 | RUI | SMQ_TERM_WEIGHT | 3 | Systemic lupus erythematosus (SMQ) |
| C1869050 | R92115649 | RUI | SMQ_TERM_WEIGHT | 0 | Anticholinergic syndrome (SMQ) |
| C1869062 | R92117581 | RUI | SMQ_TERM_WEIGHT | 0 | Retroperitoneal fibrosis (SMQ) |
| C0042510 | R92093171 | RUI | SMQ_TERM_WEIGHT | 0 | Ventricular fibrillation paroxysm |
| C1328585 | R92102276 | RUI | SMQ_TERM_WEIGHT | 0 | Propofol syndrome |
SMQ_TERM_LEVEL
(return to top)| CUI | METAUI | LUI | SUI | STYPE | CODE | ATN | ATV | STR |
|---|---|---|---|---|---|---|---|---|
| C0472686 | A10925505 | L0797076 | S0847563 | CODE | 10066348 | SMQ_TERM_LEVEL | 5 | Continuous hemodiafiltration |
| C0019158 | A2849382 | L0019158 | S0047899 | CODE | 10019717 | SMQ_TERM_LEVEL | 4 | Hepatitis |
| C0852988 | A1584966 | L1372261 | S1626355 | CODE | 10005820 | SMQ_TERM_LEVEL | 4 | Blood thrombin decreased |
| C0019159 | A1601768 | L0019190 | S1640906 | CODE | 10019782 | SMQ_TERM_LEVEL | 5 | Hepatitis infectious NOS |
| C0438716 | A0671443 | L0291038 | S0616413 | CODE | 10008486 | SMQ_TERM_LEVEL | 5 | Chest pressure |
| C0857192 | A2851146 | L1382417 | S1643745 | CODE | 10037893 | SMQ_TERM_LEVEL | 5 | Rash trunk & limbs |
| C0239212 | A2016887 | L0298415 | S2162859 | CODE | 10052440 | SMQ_TERM_LEVEL | 5 | Erythema ear |
| C0031157 | A1575592 | L0031157 | S1618537 | CODE | 10034688 | SMQ_TERM_LEVEL | 5 | Peritonsillar abscess NOS |
| C0857337 | A1586914 | L1373410 | S1628026 | CODE | 10006788 | SMQ_TERM_LEVEL | 5 | Burning sensation in joints |
| C0234221 | A4363255 | L0277697 | S0354253 | CODE | 10062860 | SMQ_TERM_LEVEL | 5 | Acroparesthesia |
| C0006870 | A1587973 | L0006870 | S1628930 | CODE | 10012341 | SMQ_TERM_LEVEL | 5 | Dependence on cannabis |
| C0155967 | A0949729 | L0182838 | S0891525 | CODE | 10017838 | SMQ_TERM_LEVEL | 5 | Gastric ulcer, acute with haemorrhage |
| C0333549 | A7161353 | L1380767 | S1640428 | CODE | 10019013 | SMQ_TERM_LEVEL | 4 | Haemorrhagic infarction |
| C0020581 | A13074484 | L0280795 | S1622235 | CODE | 10019528 | SMQ_TERM_LEVEL | 5 | Hemorrhage ant chamber eye |
| C0153174 | A0268320 | L0180007 | S0244529 | CODE | 10042923 | SMQ_TERM_LEVEL | 5 | Syphilitic ruptured cerebral aneurysm |
| C0042134 | A1115052 | L0042134 | S1057043 | CODE | 10046788 | SMQ_TERM_LEVEL | 4 | Uterine haemorrhage |
| C0018924 | A2601577 | L0286278 | S2939622 | CODE | 10059609 | SMQ_TERM_LEVEL | 5 | Joint bleeding |
| C0151502 | A1580289 | L0161380 | S1622462 | CODE | 10021653 | SMQ_TERM_LEVEL | 5 | Increased anticoagulant effect |
| C1994994 | A0411260 | L0300129 | S0370873 | CODE | 10015608 | SMQ_TERM_LEVEL | 5 | Excessive thirst |
MPS
(return to top)| CUI | METAUI | LUI | SUI | STYPE | CODE | ATN | ATV | STR |
|---|---|---|---|---|---|---|---|---|
| C0154206 | A1577141 | L1368072 | S1619851 | SDUI | 10001371 | MPS | 10014698 | Adrenal medulla hyperfunction |
| C0004509 | A0028374 | L0004509 | S0017219 | SDUI | 10003883 | MPS | 10038604 | Azoospermia |
| C0855094 | A1582247 | L1370819 | S1624108 | SDUI | 10003907 | MPS | 10029104 | B-cell lymphoma stage IV |
| C0854279 | A1582832 | L1371195 | S1624593 | SDUI | 10004153 | MPS | 10029205 | Basal ganglion degeneration |
| C0854066 | A1573721 | L1366374 | S1617103 | SDUI | 10004877 | MPS | 10022891 | Biopsy spinal cord abnormal |
| C0853427 | A1583876 | L1371742 | S1625486 | SDUI | 10004881 | MPS | 10022891 | Biopsy stomach normal |
| C0855627 | A1583521 | L1371584 | S1625222 | SDUI | 10005371 | MPS | 10022891 | Blood bilirubin unconjugated normal |
| C0392003 | A1586264 | L0758428 | S1627425 | SDUI | 10006217 | MPS | 10021881 | Breast cellulitis |
| C0006262 | A0661140 | L0006262 | S0605259 | SDUI | 10006437 | MPS | 10038738 | Bronchial fistula |
| C0521544 | A0893227 | L0723272 | S0834805 | SDUI | 10008023 | MPS | 10029205 | Cerebellar artery thrombosis |
| C0549545 | A2850541 | L1030705 | S1617439 | SDUI | 10009669 | MPS | 10022891 | Clot retraction abnormal |
| C0009417 | A0041143 | L0009417 | S0026645 | SDUI | 10010069 | MPS | 10022891 | Colposcopy |
| C0011609 | A7160665 | L0013174 | S0004902 | SDUI | 10013687 | MPS | 10040785 | Drug eruption |
| C0266328 | A0550449 | L0390659 | S0483237 | SDUI | 10014172 | MPS | 10010331 | Ectopic ureter |
| C0553891 | A1598602 | L1379427 | S1638208 | SDUI | 10015894 | MPS | 10042613 | Extubation |
| C0855235 | A1599079 | L1379615 | S1638617 | SDUI | 10016374 | MPS | 10037175 | Feelings of worthlessness |
| C0221829 | A1592162 | L0292802 | S1632601 | SDUI | 10016387 | MPS | 10042613 | Female condom |
| C0744032 | A1599330 | L1379721 | S1638831 | SDUI | 10016687 | MPS | 10042613 | Finger repair operation |
| C0852925 | A1600370 | L1380190 | S1639673 | SDUI | 10017982 | MPS | 10017947 | Gastrointestinal necrosis |
SMQ_ALGO
(return to top)| CUI | METAUI | LUI | SUI | STYPE | CODE | ATN | ATV | STR |
|---|---|---|---|---|---|---|---|---|
| C1869006 | A12057156 | L6511616 | S7585752 | SDUI | 20000001 | SMQ_ALGO | N | Torsade de pointes/QT prolongation (SMQ) |
| C1869008 | A12056800 | L6511448 | S7585289 | SDUI | 20000003 | SMQ_ALGO | N | Acute renal failure (SMQ) |
| C1869009 | A12057733 | L6511462 | S7585426 | SDUI | 20000005 | SMQ_ALGO | N | Hepatic disorders (SMQ) |
| C1869013 | A12056802 | L6511443 | S7585261 | SDUI | 20000009 | SMQ_ALGO | N | Cholestasis and jaundice of hepatic origin (SMQ) |
| C1869015 | A12056621 | L6511665 | S7585509 | SDUI | 20000011 | SMQ_ALGO | N | Liver neoplasms, malignant and unspecified (SMQ) |
| C1869017 | A12057343 | L6511463 | S7585427 | SDUI | 20000013 | SMQ_ALGO | N | Hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions (SMQ) |
| C1869018 | A12057698 | L6511446 | S7585282 | SDUI | 20000014 | SMQ_ALGO | N | Congenital, familial, neonatal and genetic disorders of the liver (SMQ) |
| C1869024 | A12057520 | L6511492 | S7585682 | SDUI | 20000020 | SMQ_ALGO | N | Severe cutaneous adverse reactions (SMQ) |
| C1869038 | A12057161 | L6511588 | S7585462 | SDUI | 20000021 | SMQ_ALGO | A or (B and C) or (D and (B or C)) | Anaphylactic reaction (SMQ) |
| C1869025 | A12057005 | L6511764 | S7585273 | SDUI | 20000022 | SMQ_ALGO | A or (B and C) | Acute pancreatitis (SMQ) |
| C1869039 | A12057871 | L6511451 | S7585311 | SDUI | 20000035 | SMQ_ALGO | N | Depression and suicide/self-injury (SMQ) |
| C1869040 | A12057699 | L6511910 | S7585713 | SDUI | 20000037 | SMQ_ALGO | N | Suicide/self-injury (SMQ) |
| C1869102 | A12057522 | L6511581 | S7585409 | SDUI | 20000039 | SMQ_ALGO | N | Haemorrhage terms (excl laboratory terms) (SMQ) |
| C1869044 | A12057523 | L6511722 | S7585477 | SDUI | 20000042 | SMQ_ALGO | N | Interstitial lung disease (SMQ) |
| C1869048 | A12057163 | L6511854 | S7585728 | SDUI | 20000046 | SMQ_ALGO | N | Taste and smell disorders (SMQ) |
| C1869050 | A12057347 | L6511537 | S7585552 | SDUI | 20000048 | SMQ_ALGO | A or (B and C and D) | Anticholinergic syndrome (SMQ) |
| C1869100 | A12056985 | L6511495 | S7585725 | SDUI | 20000054 | SMQ_ALGO | N | Tachyarrhythmias (incl supraventricular and ventricular tachyarrhythmias) (SMQ) |
| C1869058 | A12057872 | L6511566 | S7585252 | SDUI | 20000060 | SMQ_ALGO | N | Cerebrovascular disorders (SMQ) |
| C1869060 | A12057703 | L6511830 | S7585484 | SDUI | 20000063 | SMQ_ALGO | N | Ischaemic cerebrovascular conditions (SMQ) |
SMQ_LEVEL
(return to top)| CUI | METAUI | LUI | SUI | STYPE | CODE | ATN | ATV | STR |
|---|---|---|---|---|---|---|---|---|
| C1869009 | A12057733 | L6511462 | S7585426 | SDUI | 20000005 | SMQ_LEVEL | 1 | Hepatic disorders (SMQ) |
| C1869012 | A12057868 | L6511726 | S7585510 | SDUI | 20000008 | SMQ_LEVEL | 3 | Liver related investigations, signs and symptoms (SMQ) |
| C1869013 | A12056802 | L6511443 | S7585261 | SDUI | 20000009 | SMQ_LEVEL | 3 | Cholestasis and jaundice of hepatic origin (SMQ) |
| C1869014 | A12057518 | L6511652 | S7585428 | SDUI | 20000010 | SMQ_LEVEL | 4 | Hepatitis, non-infectious (SMQ) |
| C1869018 | A12057698 | L6511446 | S7585282 | SDUI | 20000014 | SMQ_LEVEL | 2 | Congenital, familial, neonatal and genetic disorders of the liver (SMQ) |
| C1869020 | A12057519 | L6511530 | S7585506 | SDUI | 20000016 | SMQ_LEVEL | 2 | Liver infections (SMQ) |
| C1869038 | A12057161 | L6511588 | S7585462 | SDUI | 20000021 | SMQ_LEVEL | 1 | Anaphylactic reaction (SMQ) |
| C1869027 | A12056622 | L6511474 | S7585499 | SDUI | 20000024 | SMQ_LEVEL | 1 | Angioedema (SMQ) |
| C1869029 | A12056804 | L6511636 | S7585322 | SDUI | 20000026 | SMQ_LEVEL | 1 | Dyslipidaemia (SMQ) |
| C1869035 | A12057345 | L6511725 | S7585492 | SDUI | 20000032 | SMQ_LEVEL | 1 | Lack of efficacy/effect (SMQ) |
| C1869037 | A12057160 | L6511794 | S7585607 | SDUI | 20000034 | SMQ_LEVEL | 1 | Peripheral neuropathy (SMQ) |
| C1869039 | A12057871 | L6511451 | S7585311 | SDUI | 20000035 | SMQ_LEVEL | 1 | Depression and suicide/self-injury (SMQ) |
| C1869102 | A12057522 | L6511581 | S7585409 | SDUI | 20000039 | SMQ_LEVEL | 2 | Haemorrhage terms (excl laboratory terms) (SMQ) |
| C1869042 | A12057700 | L6511649 | S7585408 | SDUI | 20000040 | SMQ_LEVEL | 2 | Haemorrhage laboratory terms (SMQ) |
| C1869043 | A12057346 | L6511583 | S7585435 | SDUI | 20000041 | SMQ_LEVEL | 1 | Hyperglycaemia/new onset diabetes mellitus (SMQ) |
| C1869045 | A12057162 | L6511592 | S7585485 | SDUI | 20000043 | SMQ_LEVEL | 1 | Ischaemic heart disease (SMQ) |
| C1869046 | A12057701 | L6511894 | S7585566 | SDUI | 20000044 | SMQ_LEVEL | 1 | Neuroleptic malignant syndrome (SMQ) |
| C1869049 | A12056984 | L6511672 | S7585557 | SDUI | 20000047 | SMQ_LEVEL | 2 | Myocardial infarction (SMQ) |
| C1869050 | A12057347 | L6511537 | S7585552 | SDUI | 20000048 | SMQ_LEVEL | 1 | Anticholinergic syndrome (SMQ) |
SMQ_STATUS
(return to top)| CUI | METAUI | LUI | SUI | STYPE | CODE | ATN | ATV | STR |
|---|---|---|---|---|---|---|---|---|
| C1869006 | A12057156 | L6511616 | S7585752 | SDUI | 20000001 | SMQ_STATUS | A | Torsade de pointes/QT prolongation (SMQ) |
| C1869008 | A12056800 | L6511448 | S7585289 | SDUI | 20000003 | SMQ_STATUS | A | Acute renal failure (SMQ) |
| C1869091 | A12057875 | L6511505 | S7585241 | SDUI | 20000004 | SMQ_STATUS | A | Cardiac failure (SMQ) |
| C1869009 | A12057733 | L6511462 | S7585426 | SDUI | 20000005 | SMQ_STATUS | A | Hepatic disorders (SMQ) |
| C1869012 | A12057868 | L6511726 | S7585510 | SDUI | 20000008 | SMQ_STATUS | A | Liver related investigations, signs and symptoms (SMQ) |
| C1869013 | A12056802 | L6511443 | S7585261 | SDUI | 20000009 | SMQ_STATUS | A | Cholestasis and jaundice of hepatic origin (SMQ) |
| C1869014 | A12057518 | L6511652 | S7585428 | SDUI | 20000010 | SMQ_STATUS | A | Hepatitis, non-infectious (SMQ) |
| C1869015 | A12056621 | L6511665 | S7585509 | SDUI | 20000011 | SMQ_STATUS | A | Liver neoplasms, malignant and unspecified (SMQ) |
| C1869018 | A12057698 | L6511446 | S7585282 | SDUI | 20000014 | SMQ_STATUS | A | Congenital, familial, neonatal and genetic disorders of the liver (SMQ) |
| C1869020 | A12057519 | L6511530 | S7585506 | SDUI | 20000016 | SMQ_STATUS | A | Liver infections (SMQ) |
| C1869022 | A12057158 | L6511902 | S7585629 | SDUI | 20000018 | SMQ_STATUS | A | Pregnancy-related hepatic disorders (SMQ) |
| C1869024 | A12057520 | L6511492 | S7585682 | SDUI | 20000020 | SMQ_STATUS | A | Severe cutaneous adverse reactions (SMQ) |
| C1869038 | A12057161 | L6511588 | S7585462 | SDUI | 20000021 | SMQ_STATUS | A | Anaphylactic reaction (SMQ) |
| C1869026 | A12056983 | L6511876 | S7585355 | SDUI | 20000023 | SMQ_STATUS | A | Agranulocytosis (SMQ) |
| C1869029 | A12056804 | L6511636 | S7585322 | SDUI | 20000026 | SMQ_STATUS | A | Dyslipidaemia (SMQ) |
| C1869030 | A12057521 | L6511580 | S7585405 | SDUI | 20000027 | SMQ_STATUS | A | Haematopoietic cytopenias (SMQ) |
| C1869035 | A12057345 | L6511725 | S7585492 | SDUI | 20000032 | SMQ_STATUS | A | Lack of efficacy/effect (SMQ) |
| C1869039 | A12057871 | L6511451 | S7585311 | SDUI | 20000035 | SMQ_STATUS | A | Depression and suicide/self-injury (SMQ) |
| C1869040 | A12057699 | L6511910 | S7585713 | SDUI | 20000037 | SMQ_STATUS | A | Suicide/self-injury (SMQ) |
SMQ_SOURCE
(return to top)| CUI | METAUI | LUI | SUI | STYPE | CODE | ATN | ATV | STR |
|---|---|---|---|---|---|---|---|---|
| C1869007 | A12057867 | L6511681 | S7585665 | SDUI | 20000002 | SMQ_SOURCE | Basic requirements for the use of terms for reporting adverse drug reactions (IV). Pharmacoepidemiology and Drug Safety 1993; 2:149-153. Myopathy. Reporting Adverse Drug Reactions: Definitions of Terms and Criteria for Their Use. Bankowski Z, Bruppacher R, Crusius I et al (Eds). Council for International Organizations of Medical Sciences: Geneva, 1999, pg. 16-17. Poels PJE and Gabreels FJM. Rhabdomyolysis: a review of the literature. Clin Neurol Neurosurg 1993; 95:175-192. Omar MA, Wilson JP, and Cox, TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Annals Pharmacother 2001; 35:1096-1107. Prendergast BD and George CF. Drug-induced rhabdomyolysis - mechanisms and management. Postgrad Med J 1993; 69:333-336. | Rhabdomyolysis/myopathy (SMQ) |
| C1869038 | A12057161 | L6511588 | S7585462 | SDUI | 20000021 | SMQ_SOURCE | 1 The Merck Manual. 15th edition. Merck, Sharp & Dohme Research Laboratories. (1987): 306-7 | Anaphylactic reaction (SMQ) |
| C1869025 | A12057005 | L6511764 | S7585273 | SDUI | 20000022 | SMQ_SOURCE | 1. Anonymous. Pancreatitis. Reporting Adverse Drug Reactions: Definitions of Terms and Criteria for Their Use. Bankowski Z, Bruppacher R, Crusius I et al (Eds). Council for International Organizations of Medical Sciences: Geneva, 1999, pp 53-54 2. Berardi RR and Montgomery PA. Pancreatitis. Pharmacotherapy: A Pathophysiologic Approach (5th Ed). DiPiro JT, Talbert RL, Yee GC et al (Eds). McGraw-Hill: New York, NY. 1999. pp 701-715 3. Greenberger NJ, Toskes PP, and Isselbacher KJ. Acute and chronic pancreatitis. Harrison's Principles of Internal Medicine (14th Ed). Fauci AS, Braunwald E, Isselbacher KJ et al (Eds). McGraw-Hill: New York, NY. 1998. pp 1741-1752 | Acute pancreatitis (SMQ) |
| C1869028 | A12057870 | L6511607 | S7585649 | SDUI | 20000025 | SMQ_SOURCE | 1. CIOMS publication, "Reporting Adverse Drug Reactions: Definitions of Terms and Criteria for their Use", pp 89 - 90, 1999.2. The Merck Manual, Seventeenth Edition, pp 556 - 568, 1999. 3. "Harrison's Principles of Internal Medicine", 14th edition, pp 1419 - 1426, 1998. | Asthma/bronchospasm (SMQ) |
| C1869029 | A12056804 | L6511636 | S7585322 | SDUI | 20000026 | SMQ_SOURCE | 1. Harrison's Principles of Internal Medicine, 16th Edition 2. Ross R: Atherosclerosis - an in?ammatory disease. N Engl J Med340:115-126,1999. 3. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Adult Treatment Panel III)Third Report of the National Cholesterol Education Program (NCEP) NIH - U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES - NIH Publication No.02-5215 September 2002 | Dyslipidaemia (SMQ) |
| C1869037 | A12057160 | L6511794 | S7585607 | SDUI | 20000034 | SMQ_SOURCE | Bankowski Z, Bruppacher R, Crusius I et al. Reporting adverse drug reactions, definition of terms and criteria for their use. Council for International Organizations of Medical Sciences (CIOMS), 1999 p 32 | Peripheral neuropathy (SMQ) |
| C1869041 | A12056806 | L6511720 | S7585411 | SDUI | 20000038 | SMQ_SOURCE | Dorland's Illustrated Medical Dictionary, Saunders, Philadelphia, 2000 | Haemorrhages (SMQ) |
| C1869043 | A12057346 | L6511583 | S7585435 | SDUI | 20000041 | SMQ_SOURCE | 1. Oki JC and Isley WL. Diabetes mellitus. Pharmacotherapy: A Pathophysiologic Approach (5th Ed). DiPiro JT, Talbert RL, Yee GC et al (Eds). McGraw-Hill: New York, 2002. pg. 1335-1358. 2. Powers AC. Diabetes mellitus. Harrison's Principles of Internal Medicine (15th Ed). Braunwald E, Fauci AS, Kasper DL et al (Eds). McGraw-Hill: New York, 2001. pg. 2109-2137. 3. Vanrenterghem YFC. Which calcerineurin inhibitor is preferred in renal transplantation: tacrolimus or cyclosporine? Curr Opin Nephrol Hypertension 1999; 8(6):669-674. 4. Fraenkel PG, Rutkove SB, Matheson JK et al. Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer. J Immunother 2002; 25(4):373-378. 5. Costa J. Corticotrophins and corticosteroids. Meyler's Side Effects of Drugs (14th Ed). Dukes MNG (Ed). Elsevier:Amsterdam, 2000. pg. 1364-1395. 6. Coates P. Miscellaneous hormones. . Meyler's Side Effects of Drugs (14th Ed). Dukes MNG (Ed). Elsevier:Amsterdam, 2000. pg. 1520-1526. 7. Heck AM, Yanovski LA, and Calis KA. Pituitary gland disorders. Pharmacotherapy: A Pathophysiologic Approach (5th Ed). DiPiro JT, Talbert RL, Yee GC et al (Eds). McGraw-Hill: New York, 2002. pg. 1395-1411. 8. Currier J. Management of metabolic complications of therapy. AIDS 2002; 16(Suppl 4):S171-S176. 9. Fantry LE. Protease inhibitor-associated diabetes mellitus: a potential cause of morbidity and mortality. JAIDS 2003; 32: 243-244. 10. Henderson DC. Atypical antipsychotic-induced diabetes mellitus. CNS Drugs 2002; 16(2):77-89. 11. Citrome LL. The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Drugs of Today 2004; 40(5):445-464. 12. Melkersson K and Dahl M-L. Adverse metabolic effe | Hyperglycaemia/new onset diabetes mellitus (SMQ) |
| C1869044 | A12057523 | L6511722 | S7585477 | SDUI | 20000042 | SMQ_SOURCE | Not provided | Interstitial lung disease (SMQ) |
| C1869045 | A12057162 | L6511592 | S7585485 | SDUI | 20000043 | SMQ_SOURCE | Harrison's Textbook of Internal Medicine | Ischaemic heart disease (SMQ) |
| C1869046 | A12057701 | L6511894 | S7585566 | SDUI | 20000044 | SMQ_SOURCE | 1) Levenson JL. Neuroleptic malignant syndrome. Amer J Psychiatry 1985; 142(10):1137-1145. 2) Caroff SN and Mann SC. Neuroleptic malignant syndrome. Medical Clinics of North America 1993; 77(1):185-202. 3) Neuroleptic malignant syndrome. Diagnostic and Statistical Manual of Mental Disorders (4th Ed). American Psychiatric Association: Washington DC, 1994, pg. 739-742. 4) Velamoor VR. Neuroleptic malignant syndrome: recognition, prevention and management. Drug Safety 1998; 19(1):73-82. 5) Neuroleptic malignant syndrome. Reporting Adverse Drug Reactions: Definitions of Terms and Criteria for Their Use. Bankowski Z, Bruppacher R, Crusius I et al (Eds). Council for International Organizations of Medical Sciences: Geneva, 1999, pg. 31-32. 6) Simpson GM, Pi EH, and Sramek JJ. Neuroleptic and antipsychotic drugs. Meyler's Side Effects of Drugs (14th Ed). Dukes MNG and Aronson JK (Eds). Elsevier: New York, 2000, pg. 139-163. 7) Crismon ML and Dorson PG. Schizophrenia. Pharmacotherapy: A Pathophysiologic Approach (5th Ed). DiPiro JT, Talbert RL, Yee GC et al (Eds). McGraw-Hill: New York, 2002, pg. 1219-1242. 8) Hasan S and Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Amer J Psychiatry 1998; 155(8):1113-1116. 9) Caroff SN, Mann SC, and Campbell EC. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatric Annals 2000; 30(5):314-321. 10) Ananth J, Parameswaran S, and Gunatilake S et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65(4):464-470. | Neuroleptic malignant syndrome (SMQ) |
| C1869047 | A12056625 | L6511688 | S7585723 | SDUI | 20000045 | SMQ_SOURCE | 1. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 1999;42:1785-96. 2. Hellman DB, Stone JH. Arthritis and musculoskeletal disorders. In: Tierney, Jr. LM, McPhee SJ, Papadakis MA, editors. Current medical diagnosis and treatment. 43rd ed. New York: McGraw-Hill Companies, Inc.; 2004. Available via intranet at STAT!Ref Online Medical Database. Teton Data Systems, Jackson, Wyo. (Version 3.3.6, 2004). 3. Hahn BH. Disorders of the immune system, connective tissues, and joints. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, editors. Harrison's principles of internal medicine. 16th ed. New York: McGraw-Hill Companies; 2005. Available via intranet at STAT!Ref Online Medical Database. Teton Data Systems, Jackson, Wyo. (Version 3.3.6, 2004). 4. Diffuse connective tissue disease. In: Beers MH, Berkow R, editors. The merck manual of diagnosis and therapy. 11th ed. Whitehouse Station: Merck Research Laboratories; 1999. Available via intranet at STAT!Ref Online Medical Database. Teton Data Systems, Jackson, Wyo. (Version 3.3.6, 2004). 5. Trethewey P. Systemic Lupus Erythematosus. Dimens Crit Care Nurs 2004;23:111-5. 6. CIOMS Publication, "Reporting Adverse Drug Reactions: Definitions of Terms and Criteria for their Use", pp 19 - 20, 1999. 7. The Merck Manual, Seventeenth Edition, pp 426 - 430, 1999 8. "Harrison's Principles of Internal Medicine", 14th edition, pp 1874 - 1880, 1998 9. Stratton MA Drug-induced systemic lupus erethemetosis. Clin Pharm 1985: 4:567-63 10. Yung R, Chang S, Hemati N et al. Mechanisms of drug-induced lupus. IV. Comparison of procainamide and hydralazine with analogs in vitro and | Systemic lupus erythematosus (SMQ) |
| C1869048 | A12057163 | L6511854 | S7585728 | SDUI | 20000046 | SMQ_SOURCE | 1. The Merck Manual, 17th ed., 1999, p 687 2. Harrison's Principles of Internal Medicine, 14th ed., 1998, pp 173 - 175 3. Doty, RL et al. Influences of antihypertensive and antihyperlipidemic drugs on the senses of taste and smell: a review. J Hypertens21: 1805 -1813 4. Stedman's Medical Dictionary, 27th ed., 2000. | Taste and smell disorders (SMQ) |
| C1869051 | A12057164 | L6511628 | S7585238 | SDUI | 20000049 | SMQ_SOURCE | 1. Bankowski Z, Bruppacher R, Crusius I et al. Reporting adverse drug reactions, definition of terms and criteria for their use. Council for International Organizations of Medical Sciences (CIOMS), 1999. Page 78. 2. Harrison's Principles of Internal Medicine 16th ed, Mc Graw Hill, 2005, pp 1333-58. | Cardiac arrhythmias (SMQ) |
| C1869058 | A12057872 | L6511566 | S7585252 | SDUI | 20000060 | SMQ_SOURCE | The Merck Manual (Seventeenth Edition), 1999 | Cerebrovascular disorders (SMQ) |
| C1869060 | A12057703 | L6511830 | S7585484 | SDUI | 20000063 | SMQ_SOURCE | The Merck Manual (Seventeenth Edition), 1999 | Ischaemic cerebrovascular conditions (SMQ) |
| C1869062 | A12057349 | L6511487 | S7585664 | SDUI | 20000065 | SMQ_SOURCE | 1. CIOMS, Reporting Adverse Drug Reactions, 1999, p 20-21. 2. Khan, AN. Retroperitoneal fibrosis. 13 September 2002. http://www.emedicine.com/radio/topic605.htm. 3. Diamond, JR. Clinical manifestations and diagnosis of retroperitoneal fibrosis. UpToDate(r), 27 February 2005 http://www.utdol.com/ | Retroperitoneal fibrosis (SMQ) |
| C1869063 | A12056987 | L6511611 | S7585685 | SDUI | 20000066 | SMQ_SOURCE | 1. Harrison's Principles of Internal Medicine 16th ed, Mc Graw Hill, 2005, pp 1581, 1600-1605 2. Dorland's Illustrated Medical Dictionary, 28th ed, Philadelphia WB Saunders Co. 3. Reporting Adverse Drug Reactions, Definitions and Criteria for Their Use, CIOMS, Geneva, 1999 4. Harrison's Principles of Internal Medicine 16th ed, Mc Graw Hill, 2005, pp 1367-71 | Shock (SMQ) |
| C1869064 | A12057734 | L6511848 | S7585686 | SDUI | 20000067 | SMQ_SOURCE | 1. Harrison's Principles of Internal Medicine 16th ed, Mc Graw Hill, 2005, pp 1581, 1600-1605 2. Dorland's Illustrated Medical Dictionary, 28th ed, Philadelphia WB Saunders Co. 3. Reporting Adverse Drug Reactions, Definitions and Criteria for Their Use, CIOMS, Geneva, 1999 4. Harrison's Principles of Internal Medicine 16th ed, Mc Graw Hill, 2005, pp 1367-71 | Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (SMQ) |
SOS
(return to top)| CUI | METAUI | LUI | SUI | STYPE | CODE | ATN | ATV | STR |
|---|---|---|---|---|---|---|---|---|
| C1869006 | A12057156 | L6511616 | S7585752 | SDUI | 20000001 | SOS | 1. Includes sudden and cardiac death terms as this is a frequent association with torsade de pointes. | Torsade de pointes/QT prolongation (SMQ) |
| C1869007 | A12057867 | L6511681 | S7585665 | SDUI | 20000002 | SOS | 1. Renal impairment/failure terms included because of the frequent association with rhabdomyolysis | Rhabdomyolysis/myopathy (SMQ) |
| C1869091 | A12057875 | L6511505 | S7585241 | SDUI | 20000004 | SOS | The CIOMS Working Group discussed in detail whether an algorithm could be applied to this SMQ based on the definition of cardiac failure provided. Such an algorithm, however, has not been tested by the CIOMS Working Group, therefore, the Working Group is requesting users to comment on the practical relevance of an algorithm approach. Such an algorithm could involve broad tersmsas follows: one oedema term, one dyspnoea term plus one clinical/sign/symptom or investigation making up 3 terms in total | Cardiac failure (SMQ) |
| C1869038 | A12057161 | L6511588 | S7585462 | SDUI | 20000021 | SOS | The following algorithm is used: All narrow search terms as well as: If one term from category B and one term from category C is present, or If one term from (category B or category C) plus one term from category D. | Anaphylactic reaction (SMQ) |
| C1869025 | A12057005 | L6511764 | S7585273 | SDUI | 20000022 | SOS | To apply algorithm - A report is considered a relevant case for further review if: 1) it includes a term from Category A (Narrow terms) OR 2) it includes at least one term from Category B (the list of laboratory values) and at least one term from Category C (the list of signs and symptoms) | Acute pancreatitis (SMQ) |
| C1869026 | A12056983 | L6511876 | S7585355 | SDUI | 20000023 | SOS | If possible, full blood counts and repeated white blood cell counts should be reported, sought for in follow up, and coded. Concerning database queries with broad search terms, additionally coded data on hematological values help to find relevant cases more easily. In case laboratory values are not coded in a database, individual review is then needed to decide upon relevance in the context of agranulocytosis. | Agranulocytosis (SMQ) |
| C1869035 | A12057345 | L6511725 | S7585492 | SDUI | 20000032 | SOS | At the present time, this SMQ is most appropriate to drugs; blood components/derivatives; and cellular, tissue, and gene therapy products. It is less appropriate to vaccine products, which seem better suited to the specialized searches described in this document. This SMQ is not appropriate to devices. This SMQ can be modfied by the user for specific product types and classes. Please see the SMQ Introductory Guide for details. | Lack of efficacy/effect (SMQ) |
| C1869036 | A12057159 | L6511663 | S7585493 | SDUI | 20000033 | SOS | Testing in two regulatory databases confirmed that the term list is adequate; in one regulatory database, the term "acidosis" identified cases, but this may be a phenomenon of the database characteristics (coding of verbatims to terms of an older terminology or other coding conventions). | Lactic acidosis (SMQ) |
| C1869039 | A12057871 | L6511451 | S7585311 | SDUI | 20000035 | SOS | PTs Intentional overdose and Poisoning deliberate were included in both the Depression search and the Suicide/self-injury search since they include LLTs suggestive of suicide or self-injury. However, inclusion of these PTs (particularly PT Intentional overdose) substantially increased the number of cases identified by both the depression and suicide/self-injury searches in phase I testing. It was the practice of the testing company to encode any case where the patient was prescribed a dose that exceeded the maximum-labeled daily dose as an intentional overdose, regardless of whether or not an overdose was being reported. Therefore, many of these cases do not involve true "overdoses". For databases where this is a common practice, it would not be unreasonable to conduct an initial search excluding these two PTs. For databases where this is not a common practice, these two PTs should be included routinely in both searches. | Depression and suicide/self-injury (SMQ) |
| C1869041 | A12056806 | L6511720 | S7585411 | SDUI | 20000038 | SOS | PT Blood urine was included although it could be interpreted as a lab test only without stating explicitly that blood was present in urine. However, this term is usually used in order to describe the finding of blood in urine. Note: Coders should have chosen PT Blood urine present if the intent was to code blood being present in the urine (macroscopically even without test). | Haemorrhages (SMQ) |
| C1869043 | A12057346 | L6511583 | S7585435 | SDUI | 20000041 | SOS | In phase I testing (company database), some broad search terms PTs (Blood cholesterol increased, Blood triglycerides increased, Weight decreased, and Weight increased) retrieved considerable "noise", but this may be dependent on the drugs selected for testing. The CIOMS WG has concluded that these PTs need to be included for completeness sake, and if the narrow search identifies a sufficient number of cases for a review then cases reporting only these PTs may not need to be reviewed further. However, should the narrow search return an insufficient number of cases for review, then cases reporting these PTs should be reviewed to determine if the patient in those cases appear to be at high risk for subsequent development of diabetes mellitus or hyperglycemia. Testing in the regulatory database similarly retrieved "noise" for PT Weight increased; however, the CIOMS WG development team agreed that this term is relevant for the scope of the SMQ and should remain in the query for now. MedDRA users are asked to specifically focus on this term during phase II testing and provide feedback on its overall utility for this SMQ | Hyperglycaemia/new onset diabetes mellitus (SMQ) |
| C1869046 | A12057701 | L6511894 | S7585566 | SDUI | 20000044 | SOS | Algorithm : Category A: specific reports of NMS or the similar conditions serotonin syndrome or malignant hyperthermia; Category B (fever-related PTs); Category C (muscle rigidity or injury-related PTs); Category D (other relevant NMS-related PTs) Cases to be selected for further review would include any cases reporting at least one of the PTs listed for Category A or any case reporting some combination of at least one PT from each of the three groups of PTs listed as Categories B, C and D. | Neuroleptic malignant syndrome (SMQ) |
| C1869047 | A12056625 | L6511688 | S7585723 | SDUI | 20000045 | SOS | Use of weighted algorithm in this SMQ: 1. The PTs mentioned in the case report are grouped according to the pre-determined categories. Occurrence of multiple PTs within a category is counted only once 2. The category that the term is attributed to is then multiplied by its empirically pre-determined "weight" (for example - 3 for categories Haematologic disorder, Serositis, and Immunologic disorder) and summed for all the categories 3. If this sum is greater than 6, it is proposed that the case report qualifies as a suspected SLE case report. For example, a case report which has PTs in the categories of Hematologic disorder (3), Immunologic disorder (3) and Renal disorder (1) will classify as a SLE broad search case report (3 + 3 + 1 = 7) | Systemic lupus erythematosus (SMQ) |
| C1869048 | A12057163 | L6511854 | S7585728 | SDUI | 20000046 | SOS | In phase I testing, cases in a company test database describing unpleasant taste and smell of the medical substance were also coded using the same terms (e.g., PT Dysgeusia). Medical review is required to distinguish between reports of the medical disorder and the physical properties of the treatment compound | Taste and smell disorders (SMQ) |
| C1869050 | A12057347 | L6511537 | S7585552 | SDUI | 20000048 | SOS | Category A (Narrow): Cases encoding to PT Anticholinergic syndrome Categories B, C and D (Broad): Category B (Nervous system-related PTs) Category C (Psychiatric-related PTs) Category D (Other relevant anticholinergic syndrome-related PTs) Cases to be selected for further review would include any cases reporting the PT listed for Category A or any case reporting some combination of at least one PT from each of the three groups of PTs listed as Categories B, C and D. Note: cases may not include a description that includes terms from more than one SOC. If it is considered important to identify these cases then a non-algorithmic approach should be taken for the broad search; however, this approach may identify a large number of irrelevant cases. | Anticholinergic syndrome (SMQ) |
| C1869051 | A12057164 | L6511628 | S7585238 | SDUI | 20000049 | SOS | For phase II testing, subscribers are asked to test the SMQ Cardiac arrhythmias and its sub-searches with the exception of the sub-search SMQ Torsade de pointes/QT prolongation which has previously been circulated for phase II testing and is currently in production. | Cardiac arrhythmias (SMQ) |
| C1869062 | A12057349 | L6511487 | S7585664 | SDUI | 20000065 | SOS | The narrow search was able to retrieve the majority of relevant cases. The addition of PT Abdominal pain to the broad search retrieved many additional cases which would not have been retrieved by the narrow search. Thus, both PT Abdominal pain and PT Abdominal pain lower are included in this query. | Retroperitoneal fibrosis (SMQ) |
| C1869076 | A12056631 | L6511904 | S7585645 | SDUI | 20000080 | SOS | The terms Diarrhoea and Diarrhoea haemorrhagic should be included in the narrow search if the compound is an antibiotic; they should remain in the broad search if the compound is not an antibiotic. PT Clostridial infection includes LLTs for non-specific "clostridial" descriptions, as well as non-C. difficile species; cases identified via PT Clostridial infection should be carefully reviewed for relevance. | Pseudomembranous colitis (SMQ) |
| C1869077 | A12057528 | L6511822 | S7585332 | SDUI | 20000081 | SOS | In order to get all relevant terms of embolism and thrombosis, it may be necessary to combine the sub-searches of this SMQ. SMQ Cerebrovascular accidents, SMQ Vasculitis and SMQ Thrombophlebitis should also be taken into consideration. | Embolic and thrombotic events (SMQ) |
MISO
(return to top)| CUI | METAUI | LUI | SUI | STYPE | CODE | ATN | ATV | STR |
|---|---|---|---|---|---|---|---|---|
| C0851353 | A1585002 | L1372278 | S1626383 | SDUI | 10005329 | MISO | 03 | Blood and lymphatic system disorders |
| C0018799 | A1588768 | L0537218 | S1629626 | SDUI | 10007541 | MISO | 11 | Cardiac disorders |
| C0851352 | A2016522 | L1376503 | S2162599 | SDUI | 10010331 | MISO | 21 | Congenital, familial and genetic disorders |
| C0851354 | A1595679 | L1378038 | S1635566 | SDUI | 10013993 | MISO | 10 | Ear and labyrinth disorders |
| C0014130 | A1595701 | L0161501 | S1635589 | SDUI | 10014698 | MISO | 05 | Endocrine disorders |
| C0015397 | A1595746 | L0012705 | S1635657 | SDUI | 10015919 | MISO | 09 | Eye disorders |
| C0017178 | A1595807 | L0161543 | S1635716 | SDUI | 10017947 | MISO | 14 | Gastrointestinal disorders |
| C0851362 | A1577054 | L1368040 | S1619777 | SDUI | 10018065 | MISO | 22 | General disorders and administration site conditions |
| C0267792 | A2017358 | L1853427 | S2163231 | SDUI | 10019805 | MISO | 15 | Hepatobiliary disorders |
| C0021053 | A1595893 | L0161607 | S1635802 | SDUI | 10021428 | MISO | 04 | Immune system disorders |
| C0009450 | A1603505 | L1381725 | S1642343 | SDUI | 10021881 | MISO | 01 | Infections and infestations |
| C0947733 | A2017507 | L1853110 | S2163342 | SDUI | 10022117 | MISO | 24 | Injury, poisoning and procedural complications |
| C1261322 | A0976668 | L0861064 | S0919672 | SDUI | 10022891 | MISO | 23 | Investigations |
| C0851358 | A1595997 | L1378196 | S1635896 | SDUI | 10027433 | MISO | 06 | Metabolism and nutrition disorders |
| C0263660 | A2018017 | L1194718 | S2163723 | SDUI | 10028395 | MISO | 17 | Musculoskeletal and connective tissue disorders |
| C0027651 | A2018135 | L1852696 | S2163814 | SDUI | 10029104 | MISO | 02 | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
| C0027765 | A1596081 | L0297185 | S1635977 | SDUI | 10029205 | MISO | 08 | Nervous system disorders |
| C0851363 | A1592150 | L1376383 | S1632589 | SDUI | 10036585 | MISO | 19 | Pregnancy, puerperium and perinatal conditions |
| C0004936 | A1596183 | L0297219 | S1636064 | SDUI | 10037175 | MISO | 07 | Psychiatric disorders |
